CABG May Be Best for Multivessel Revascularization in T1DM

Share this content:
CABG May Be Best for Multivessel Revascularization in T1DM
CABG May Be Best for Multivessel Revascularization in T1DM

WEDNESDAY, Aug. 30, 2017 (HealthDay News) -- For patients with type 1 diabetes (T1D) undergoing a first multivessel revascularization, percutaneous coronary intervention (PCI) is associated with increased risks of coronary heart disease mortality, myocardial infarction, and repeat revascularization, compared with coronary artery bypass grafting (CABG), according to a study published online Aug. 26 in the Journal of the American College of Cardiology. The research was published to coincide with the European Society of Cardiology Congress 2017, held from Aug. 26 to 30 in Barcelona, Spain.

Thomas Nyström, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues conducted an observational cohort study involving patients with T1D who underwent a first multivessel revascularization from 1995 to 2013 (683 patients who underwent CABG and 1,863 who underwent PCI).

The researchers found that 53 percent of patients in the CABG group and 45 percent in the PCI group died during a mean follow-up of 10.6 years. Compared with CABG, PCI was associated with similar risks of all-cause mortality (hazard ratio, 1.14; 95 percent confidence interval, 0.99 to 1.32), and with elevated risks of coronary heart disease mortality (hazard ratio, 1.45; 95 percent confidence interval, 1.21 to 1.74), myocardial infarction (hazard ratio, 1.47; 95 percent confidence interval, 1.23 to 1.78), and repeat revascularization (hazard ratio, 5.64; 95 percent confidence interval, 4.67 to 6.82). There were no differences noted in the risks for stroke or heart failure.

"CABG may be the preferred strategy in patients with T1D in need of multivessel revascularization," the authors write.

One author disclosed financial ties to Actelion and Pfizer.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »